SMO biotechnologies panels Licence OK with the University of Minnesota
Barcelona, Spain, 16 May 2022. SOM Biotech (“SOM” or the “Company”), a clinical-stage biopharmaceutical company with proprietary AI-based drug discovery technology focused on orphan neurological diseases, today announces that it has signed a license agreement with the University of Minnesota.
This licensing agreement follows the completion of research under a Sponsored Research Agreement (SRA) signed in 2019, in which the University of Minnesota conducted a series of alivetroh studies of potential preclinical product candidates for Duchenne and Becker muscular dystrophy identified using SOM Biotech’s proprietary platform, SOMAIPRO. Work under the SRA has resulted in inventions spanning nine potential product candidates, which SOM has chosen to license exclusively to the University of Minnesota. SOM is currently conducting additional preclinical studies at the University of Minnesota to select the best potential candidates to advance into development for Duchenne and Becker muscular dystrophy. The project was carried out with the support of the Duchenne Parent Project Spain.
Raúl Insa, Managing Director of SOM Biotech, said: “This agreement with the University of Minnesota, a leader overall to research university, shows ee exceptional Virginiaread provided by our SMOAIPRO Platform and his unique approach to AI-based drug discovery. The research which has already been carried out by the The University of Minnesota is very encouraging and we look forward to continuinginuing only at SOM biotechnologies for bring potential innovative treatments to patients with high unmet medical needs.”
SOM Biotech successfully uses SOMAIPRO to identify effective drugs for the treatment of a specific disease, to discover new mechanisms of action and new applications for a drug, and predict the toxicity of compounds, as well as the molecular scaffolds for compounds active on a given target. Whereas other AI-based approaches use methods based on data mining, structural similarity or target structure, SOMAIPRO uses molecular fields, allowing for an increased success rate, with results achieved in the shortest possible time and significantly reducing the costs associated with drug discovery.
ENDS
For more information on SOM Biotech, please contact:
Media Contact:
Maria Zimina
[email protected]
Consilium Strategic Communications
Amber Fennell, Lindsey Neville, Giulia Lasagni
[email protected]
About the University of Minnesota
The University of Minnesota is a leading American public research university with a billion-dollar annual research enterprise that embodies its slogan, Driven to Discover. It is well-regarded among business partners for bringing researchers’ cutting-edge innovations to market through successful licensing and startup partnerships.
About SOM Biotech
SOM Biotech (www.sombiotech.com) – established in 2009 – is a biopharmaceutical company based in Barcelona, Spain. SOM has an extensive pipeline of product candidates that includes drugs for orphan neurological diseases including TTR amyloidosis, Huntington’s disease, tardive dyskinesia and phenylketonuria. The Company is committed to the accelerated discovery of therapies through proprietary computational technology based on artificial intelligence (SOMAIPRO) and develops strategic partnerships with major research centers and pharmaceutical laboratories. The Society has received partial funding for a number of its programs from the Spanish Ministries of Science and Innovation (CDTI) and Industry (ENISA).
Comments are closed.